|drug857||Carrageenan nasal and throat spray Wiki||0.35|
|drug2099||Laboratory test positive for SARS-CoV-2 virus Wiki||0.35|
|drug1397||Enoxaparin 1 mg/kg Wiki||0.35|
|drug3507||Saline nasal and throat spray Wiki||0.35|
|drug1285||Duplex ultrasound and Computed Tomography Angiography Wiki||0.35|
|drug4145||Unfractionated Heparin IV Wiki||0.35|
|drug31||18F-DX600 PET/CT Wiki||0.35|
|drug2737||Oxidative Stress ELISA Kit Wiki||0.35|
|drug4147||Unfractionated heparin SC Wiki||0.35|
|drug1206||Diagnostic examination for venous thromboembolism Wiki||0.35|
|drug4784||thromboprophylaxis with low-molecular-weight heparin or fondaparinux Wiki||0.35|
|drug1398||Enoxaparin 40 Mg/0.4 mL Injectable Solution Wiki||0.25|
|drug3989||Therapeutic anticoagulation Wiki||0.25|
|D020246||Venous Thrombosis NIH||0.41|
|D011655||Pulmonary Embolism NIH||0.35|
|D016769||Embolism and Thrombosis NIH||0.18|
|D054058||Acute Coronary Syndrome NIH||0.14|
|D020141||Hemostatic Disorders NIH||0.09|
|D001778||Blood Coagulation Disorders NIH||0.09|
|D009203||Myocardial Ischemia NIH||0.08|
|D016638||Critical Illness NIH||0.04|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
|D018352||Coronavirus Infections NIH||0.03|
|HP:0002625||Deep venous thrombosis HPO||0.41|
|HP:0002204||Pulmonary embolism HPO||0.35|
There are 8 clinical trials
Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.
Description: Incidence of cardiomyopathies and/or venous thromboembolism at day 28Measure: Determine the incidence of cardiomyopathies and venous thromboembolism Time: 28 days
Description: Incidence of mortality at day 28Measure: Mortality Time: 28 days
Description: Number of day of using mechanical ventilation for each patientsMeasure: Duration of mechanical ventilation Time: 28 days
Description: Incidence of shock at day 28Measure: shock at day 28 Time: 28 days
Description: Number of day in intensive care unitMeasure: length of stay in the intensive care unit Time: 28 days
The aim of this study is to verify if patients admitted to hospital in a medical division and in the intensive care unit for a COVID-19 infection are at higher risk of developing a VTE complication and if they actually present an increased hypercoagulable state.
Description: the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolismMeasure: the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism Time: 28 days
Description: the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolismMeasure: the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolism Time: 28 days
Worldwide observational studies indicate a significant prothrombogenic effect associated with SARS-CoV-2 infection with a high incidence of venous thromboembolism (VTE), notably life-threatening pulmonary embolism. According to recommendations for acute medical illnesses, all COVID-19 hospitalized patients should be given VTE prophylaxis such as a low molecular weight heparin (LMWH). A standard prophylactic dose (eg. Enoxaparin 4000IU once daily) could be insufficient in obese patients and VTE has been reported in patients treated with a standard prophylactic dose. In COVID-19 patients, guidelines from several international societies confirm the existence of an hypercoagulability and the importance of thromboprophylaxis but the "optimal dose is unknown" and comparative studies are needed. In view of these elements, carrying out a trial comparing various therapeutic strategies for the prevention of VTE in hospitalized patients with COVID-19 constitutes a health emergency. Thus, we hypothesize that an increased prophylactic dose of weight-adjusted LMWH would be greater than a lower prophylactic dose of LMWH to reduce the risk of life-threatening VTE in hospitalized patients. The benefit-risk balance of this increase dose will be carefully evaluated because of bleeding complications favored by possible renal / hepatic dysfunctions, drug interactions or invasive procedures in COVID-19 patients. This multicenter randomized (1:1) open-label controlled trial will randomize hospitalized adults with COVID-19 infection to weight-adjusted prophylactic dose vs. lower prophylactic dose of LMWH.
Description: Risk of deep vein thrombosis or pulmonary embolism or venous thromboembolism-related deathMeasure: Venous thromboembolism Time: 28 days
Description: Risk of major bleeding defined by the ISTHMeasure: Major bleeding Time: 28 days
Description: Risk of Major Bleeding and Clinically Relevant Non-Major Bleeding Defined by the ISTHMeasure: Major Bleeding and Clinically Relevant Non-Major Bleeding Time: 28 days
Description: Risk of Venous Thromboembolism and Major BleedingMeasure: Net Clinical Benefit Time: 28 days and 2 months
Description: Risk of venous thrombosis at other sites: e.g. superficial vein, catheters, hemodialysis access, ECMO, splanchnic, encephalic, upper limbMeasure: Venous Thromboembolism at other sites Time: 28 days
Description: Risk of arterial thrombosis at any sitesMeasure: Arterial Thrombosis Time: 28 days
Description: Risk of all-cause mortalityMeasure: All-Cause Mortality Time: 28 days and 2 months
Description: Identification of associations between the risk of venous thromboembolism and clinical (eg. past medical history of thrombosis, cardiovascular risk factors, treatments, severity of COVID-19) and laboratory variables (e.g. D-dimers, fibrinogen, CRP) collected in the eCRFMeasure: Factors associated with the risk of venous thromboembolism Time: 28 days
Severe COVID-19 patients at a high risk of venous thromboembolism. We studied patients in 2 intensive care units of university hospitals in Barcelona and Badalona, Spain. We performed a cut-off screening of deep venous thrombosis (DVT) with bilateral duplex ultrasound to 230 patients.
Description: Patients with symptomatic pulmonary embolism confirmed on the CT-angiography and those with a swollen limb and confirmed deep venous thrombosis on compression ultrasound were considered to have "symptomatic venous thromboembolisms". The remaining patients with positive limb ultrasound or CT-angiography were considered to have "asymptomatic venous thrombembolism"Measure: Venous thromboembolisms Time: 7 days
Description: Deaths from all causes during the follow-upMeasure: Deaths Time: 7 days
The purpose of this study is to investigate the prevalence of venous thromboembolism in a regional health care system (Region Östergötland, Sweden) before and during the SARS-COV-2 pandemic. In a retrospective observational study, we will review patient data, diagnostic data and treatment data over a three-month period since the onset of the SARS-COV-2 pandemic. This data will be compared with data from the corresponding time frame during the years 2015 to 2019.
This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.
Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia, or clinically silent DVTMeasure: Primary endpoint: Venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlier
Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemiaMeasure: Key secondary endpoint: Clinically evident venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlier
Published papers evaluating coagulopathy on COVID-19 patients indicate a higher incidence of thromboembolic events, sometimes, as high as 20%. Such events increase ICU admissions and are associated with death. Considering the importance of thromboembolic events concurring to deteriorate clinical state, we propose to conduct a parallel pragmatic open-label randomized controlled trial to determine the effect of therapeutic anticoagulation compared to standard care in hospitalized patients with COVID-19 and with low oxygen saturation.
Description: Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.Measure: Composite main outcome Time: up to 28 days
Description: All-cause deathMeasure: All-cause death Time: 28 days
Description: Composite outcome of ICU admission or all-cause deathMeasure: Composite outcome of ICU admission or all-cause death Time: 28 days
Description: Major bleedingMeasure: Major bleeding Time: 28 days
Description: Red Blood Cell transfusion (greater than or equal to 1 unit)Measure: Number of participants who received red blood cell transfusion Time: 28 days
Description: Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrateMeasure: Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate. Time: 28 days
Description: Hospital-free days alive up to day 28Measure: Number of hospital-free days alive up to day 28 Time: 28 days
Description: ICU-free days alive up to day 28Measure: Number of ICU-free days alive up to day 28 Time: 28 days
Description: Ventilator-free days alive up to day 28Measure: Number of ventilator-free days alive up to day 28 Time: 28 days
Description: Venous thromboembolismMeasure: Number of participants with venous thromboembolism Time: 28 days
Description: Arterial thromboembolismMeasure: Number of participants with arterial thromboembolism Time: 28 days
Description: Heparin induced thrombocytopeniaMeasure: Number of participants with heparin induced thrombocytopenia Time: 28 days
Coronavirus disease 2019 (Covid-19) is now a leading cause of death among U.S. adults. In addition to profound respiratory and multi-organ failure, hypercoagulable states and venous thromboembolism (VTE) have been increasingly reported in patients with severe Covid-19. The aim of this study is evaluate the risk of VTE related to Covid-19 infection in a real-world community-based population.
Description: VTE will be defined as a clinical encounter with evidence of acute VTE, identified by diagnosis codes, +/- radiology procedure codesMeasure: Acute venous thromboembolism (VTE) Time: From the date of first positive test for SARS-CoV-2 virus occuring after January 1, 2020, until death, disenrollment from the health system, or the end of the planned outcome assessment (March 31, 2021)
Description: Death from any causeMeasure: Death Time: From the date of first positive test for SARS-CoV-2 virus occuring after January 1, 2020, until disenrollment from the health system, or the end of the planned outcome assessment (March 31, 2021)
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports